Skip to content
Screener

Allogene Therapeutics ALLO Q2 2025 earnings

Reported August 13, 2025 · Before market open

Revenue-
EPS-$0.23Beat by $0.05
EPS estimate-$0.28

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.5K
EPS estimate-$0.13

Financials

Q2 2025

Income statement

See full
Revenue-—
Operating income-$56.8M+20.5%
Net income-$50.9M+23.2%
EPS (diluted)-$0.23+34.3%

Balance sheet

See full
Cash & equivalents$62.6M-65.4%
Total debt$87.0M-7.7%
Total equity$344.6M-33.1%
Total assets$470.6M-27.3%

Cash flow

See full
Operating cash flow-$39.0M+38.6%
CapEx$44.0K—
Free cash flow-$39.1M+38.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$273.41M-43.8%
Enterprise value$297.79M-25.5%

Returns & leverage

See full
Return on equity-55.1%+7.6pp
Debt / equity0.3×+0.1×
Current ratio8.9×-3.3×

Segments

By segment

See full
Reportable Segment-—

FAQ

When did Allogene Therapeutics report Q2 2025 earnings?
Allogene Therapeutics (ALLO) reported Q2 2025 earnings on August 13, 2025 before market open.
What were Allogene Therapeutics's Q2 2025 revenue and EPS?
Allogene Therapeutics reported revenue of - and eps of $-0.23 for Q2 2025.
Did Allogene Therapeutics beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.28 by $0.05.
How did Allogene Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 28.1% from $-0.32.
Where can I find Allogene Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001737287-25-000087) and the 10-Q periodic report (0001737287-25-000088) directly on SEC EDGAR. The filing index links above go to sec.gov.